Ken Griffin Instil Bio, Inc. Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.4 - $0.63 $63,657 - $100,260	-159,143 Reduced 77.33%	46,645 $20,000
Q2 2023 Aug 14, 2023	BUY	$0.51 - $0.67 $34,959 - $45,927	68,548 Added 49.95%	205,788 $113,000
Q1 2023 May 15, 2023	SELL	$0.6 - $0.91 $202,053 - $306,447	-336,756 Reduced 71.05%	137,240 $90,000
Q4 2022 Feb 14, 2023	BUY	$0.48 - $5.33 $89,766 - $996,779	187,013 Added 65.17%	473,996 $298,000
Q3 2022 Nov 14, 2022	SELL	$4.65 - $7.37 $293,717 - $465,526	-63,165 Reduced 18.04%	286,983 $1.39 Million

1.9M

Ticker TIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,694,000
Market Cap $8.8B
Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small ce...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.